drugset / Trial / NCT02416427

Targeting the Hippo Transducer TAZ in Breast Cancer With Statins

NCT02416427

Phase 2 Unknown 78 enrolled Regina Elena Cancer Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This pre-surgical, window-of-opportunity study is designed to investigate whether atorvastatin reduces the proliferation marker Ki-67 via modulation of the Hippo transducer TAZ.

Timeline

Start
2015-05
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg

Indications